Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance

Trial Profile

Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs GL 0817 (Primary) ; Lenalidomide; Poly ICLC
  • Indications Myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Nov 2013 to 1 Dec 2017.
    • 01 May 2017 Planned primary completion date changed from 1 Nov 2013 to 1 Aug 2017.
    • 14 Dec 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top